Welcome to our dedicated page for APR news (Ticker: APR), a resource for investors and traders seeking the latest updates and insights on APR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect APR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of APR's position in the market.
Apria reported its fourth quarter and full year 2021 financial results, highlighting a 4Q net revenue of $296.5 million, a 0.9% increase year-over-year, despite challenges including a major product recall and supply chain disruptions. Net income decreased by 34.5% to $17.0 million. Adjusted EBITDA for the quarter was $58.4 million, down 8.8%. For the full year, net revenue rose 3.3% to $1,145.3 million, with net income increasing by 40.6% to $64.9 million. Despite issues, the company expects strong demand for CPAP and ventilation products to continue.
Owens & Minor (NYSE: OMI) has announced its acquisition of Apria (NASDAQ: APR) at $37.50 per share, totaling approximately $1.45 billion in equity and $1.6 billion including assumed debt. This strategic move aims to enhance healthcare services from hospital to home, diversify revenue streams, and strengthen its Patient Direct offering. The deal, providing a premium of 26-30% over Apria’s recent share prices, is expected to close in H1 2022, pending regulatory approvals. Both companies anticipate significant synergies, positioning Owens & Minor for future growth in the $50 billion home healthcare market.
Apria, Inc. (Nasdaq: APR) announced the completion of a secondary offering of 4,500,000 shares at $31.50 per share, generating gross proceeds of $141.75 million. The selling stockholder, affiliated with Blackstone, has granted underwriters a 30-day option to purchase an additional 675,000 shares. Apria did not issue any shares and did not receive net proceeds from this offering. The underwriting was led by Citigroup and Goldman Sachs, with several other firms participating. This offering was made through a prospectus filed with the SEC.
Apria announced a secondary offering of 4,500,000 shares of its common stock at $31.50 per share, with a 30-day option for underwriters to purchase an additional 675,000 shares. The offering, led by Blackstone, is set to close on November 15, 2021, pending customary conditions. Apria will not receive proceeds from the stock sale. Citigroup and Goldman Sachs are joint lead managers for the offering, alongside several other financial institutions. This press release includes forward-looking statements and emphasizes that investors should refer to SEC filings for risk factors.
Apria announced a secondary offering of 4,500,000 shares of common stock, initiated by a selling stockholder affiliated with Blackstone. Additionally, the underwriters may purchase up to 675,000 additional shares. Importantly, Apria is not offering any shares nor will it receive proceeds from this sale. The offering's management is led by Citigroup and Goldman Sachs with Citizens Capital Markets as a co-manager. A preliminary prospectus has been filed but has not yet become effective. This press release is not an offer to sell or buy securities.
Apria reported strong third quarter results for 2021, with net revenue of $287.2 million, a 3.8% increase from the previous year. Net income surged to $22.8 million, or $0.60 per diluted share, marking a 300.1% increase. Adjusted EBITDA was $61.0 million, down 6.2% year-over-year, while Adjusted EBITDA less Patient Equipment Capex improved marginally to $38.9 million. For Q4, Apria forecasts revenue between $282 million and $298 million and is raising full-year guidance for revenue and Adjusted EBITDA. Despite supply chain challenges, the company remains optimistic.
Apria, Inc. (Nasdaq: APR) will announce its fiscal third quarter 2021 financial results on November 4, 2021, after market close. A conference call to discuss these results is scheduled for 5:00 p.m. ET the same day. Participants can join the call by dialing (833) 362-0207 for U.S. attendees or (914) 987-7676 for international callers, using conference ID 4161279. The call will also be available via live audio webcast on the company's investor relations website. A replay of the call will be accessible for 90 days following its conclusion.
On October 4, 2021, Apria, a leading home medical equipment provider, appointed Christopher G. Lee as its Chief Accounting Officer. This newly created position will have Mr. Lee overseeing all aspects of the company’s accounting function, including financial reporting and operations. With 18 years of experience and a decade with Apria, he previously served as Senior Vice President, Accounting and Finance. His leadership is expected to strengthen Apria's financial management and operational practices.
Apria, Inc. (Nasdaq: APR) reported strong second quarter results for 2021, with net revenue reaching $286.3 million, a 6.4% increase year-over-year. The company achieved a net income of $20.6 million ($0.54 per diluted share), up 153.1%, and Adjusted EBITDA of $64.4 million, up 15.5%. Apria announced a definitive agreement to acquire Airway Breathing Co., enhancing its market presence. Despite industry disruptions from the Philips/Respironics recall, Apria expects continued growth, projecting 2021 net revenue between $1.12 billion to $1.15 billion.
FAQ
What is the market cap of APR (APR)?
